Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Phase III APeX-2 and APeX-S trials of BCX 7353 show improvements in hereditary angioedema.- BioCryst Pharma

Written by | 7 Jun 2020

BioCryst Pharmaceuticals announced new data from the phase III APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily BCX 7353 (berotralstat) experienced… read more.

Phase III SELECT-CHOICE trial of Rinvoq meets primary endpoint in rheumatoid arthritis.- AbbVie

Written by | 7 Jun 2020

AbbVie announced new Phase III data from the SELECT-CHOICE clinical trial in adult patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to… read more.

Interim data from phase III HELP OLE study of Takhzyro shows efficacy in hereditary angioedema.- Takeda

Written by | 7 Jun 2020

Takeda Pharmaceutical announced findings from two new interim analyses of data from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), suggesting Takhzyro (lanadelumab) is… read more.

RECOVERY trial shows no benefit from hydroxycholoroquine as treatmant for COVID-19.- Novartis

Written by | 7 Jun 2020

In March 2020 RECOVERY was established as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine The trial has proceeded at unprecedented… read more.

Novartis phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair Breezhaler (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma.

Written by | 6 Jun 2020

Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine .. These results show that once-daily treatment with single inhaler, high-… read more.

Novartis phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair Breezhaler (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma.

Written by | 6 Jun 2020

Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine .. These results show that once-daily treatment with single inhaler, high-… read more.

Novartis phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair Breezhaler (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma.

Written by | 6 Jun 2020

Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine .. These results show that once-daily treatment with single inhaler, high-… read more.

Phase III FINCH 1 and FINCH 3 studies of GLPG 0634 show 52-week efficacy in rheumatoid arthritis.- Gilead Sciences/Galapagos

Written by | 6 Jun 2020

Gilead Sciences and Galapagos announced Week 52 results from the Phase III FINCH 1 and FINCH 3 studies of GLPG 0634 (filgotinib), an investigational, oral, selective JAK1 inhibitor,… read more.

Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response.

Written by | 6 Jun 2020

Roche announcedy that the FDA has issued an Emergency Use Authorisation (EUA) for the Elecsys IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and… read more.

Novartis phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair Breezhaler (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma.

Written by | 6 Jun 2020

Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine .. These results show that once-daily treatment with single inhaler, high-… read more.

Aurinia presents AURORA pivotal trial subgroup analysis of voclosporin for lupus nephritis at the EULAR 2020 E-Congress.

Written by | 6 Jun 2020

Aurinia Pharmaceuticals Inc. announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented at the European League Against Rheumatism (EULAR) 2020 E-Congress in… read more.

Inovio and IVI partner with Seoul National University Hospital to start phase 1/II clinical rial of Inovio’s COVID-19 DNA vaccine (INO-4800) in South Korea.

Written by | 6 Jun 2020

Inovio , the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/II clinical trial of INOVIO’s COVID-19 vaccine INO 4800… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.